About the Event
Join us for the next installment of Ophthalmology Grand Rounds featuring Brian B. Berger, M.D., on drug development for retinal disease. Berger is an ophthalmologist at Retina Consultants of Austin.
By the end of this presentation, the audience participant should be able to:
- Assess the history and current status of drug development in the United States;
- Illustrate the steps from bench to bedside with emphasis on research and regulation;
- Discuss the usage of blood vessel growth inhibitors.
- Primary: Physicians in ophthalmology
- Secondary: Internal medicine, geriatric care and physician extenders
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: PC; IPSC; P; MK; PBLI; SBP.
- IOM: Patient-centered care; work with interdisciplinary teams; use evidence-based practice; apply QI; use informatics.
- IECC: Interprofessional teamwork and team-based practice; interprofessional communication; roles and responsibilities.
Berger disclosed the following relevant financial relationships: honorariums received from Kodiak Sciences and Adverum Biotechnologies.
The Ophthalmology Department Grand Rounds planning committee members are Jane Edmond, M.D.; John Shore, M.D.; Randy Shepard; and Nicole Groote. The members of the planning committee have no relevant financial relationships to disclose.
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.